Lapo Alinari
Lapo Alinari
Explore linked clinical trials.1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type; Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type; Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type; Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | Recruiting | Phase 1 | 2026-02-27 | NCT05755087 |